

**Regd. Office :-**

330, TRIVIA Complex, Natubhai Circle,  
Racecourse, Vadodara – 390007, Gujarat, INDIA  
Phone : +91 265 2988903 / 2984803  
Website : www.chemcrux.com  
Email : girishshah@chemcrux.com



To,  
**Corporate Relations Department**  
**BSE LIMITED,**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai- 400 001

13<sup>th</sup> February 2023

Dear Sir/Madam,

**Subject:** Unaudited Standalone Financial Results for the third quarter and nine months ended 31<sup>st</sup> December 2022

**Ref:** **BSE Scrip ID: CHEMCRUX** **BSE Scrip Code: 540395**

We would like to inform that the Board of Directors in its meeting held today i.e., 13<sup>th</sup> February 2023 inter alia, considered and approved the Unaudited Standalone Financial Results for the third quarter and nine months ended 31<sup>st</sup> December 2022 as recommended by the Audit Committee.

Kindly take above as compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board Meeting commenced at 12.00 P.M. and concluded at 2:16 P.M.

Thanking you,

**For CHEMCRUX ENTERPRISES LIMITED**

*Dipika*  
Dipika Rajpal  
Company Secretary & Compliance Officer



**Factory**

4712-14, GIDC, Road South - 10, Ankleshwar - 393002 (Gujarat) India.  
Ph.: +91 2646 221427, 239737 | Email : sanjay@chemcrux.com



**INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT**

To,  
The Board of Directors,  
**Chemcrux Enterprises Limited,**

We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Chemcrux Enterprises Limited** ("The Company") for the **quarter and nine months ended 31<sup>st</sup> December 2022**, read together with the Notes thereon ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement which is the responsibility of the Company's Management and has been approved by the Board of Directors has been prepared in accordance with recognition and measurement principles laid down in IND AS 34 "Interim Financial Reporting" as prescribed u/s. 133 of the Companies Act, 2013 (the "Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on this Statement based on our review.

We conducted our review of the Financial Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free from material misstatement. A review is limited primarily to inquiries of Company Personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable Indian Accounting Standards (Ind AS) specified under section 133 of the Companies Act, 2013, together with the Notes thereon and read with relevant rules and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.





**r. j. shah & associates**  
*chartered accountants*

**R. J. Shah FCA** **D-408, Fifth Floor, Avishkar Complex, Old Padra Road, Vadodara - 390015**  
**N. R. Dholakia FCA** **T: (O) 9825031128 • e-mail: rjshahassociates@yahoo.com**

We draw your attention to the following matters:

- a) Note 2 to the Statement which informs that the Company migrated from the SME Exchange to the Main Board on 5th May, 2022. Hence, the Company has first-time adopted IND AS during the Quarter with transition period date of 1st April, 2021.
- b) Note 4 to the Statement which informs that since the Company was listed on SME Exchange till the end of previous year, it was not preparing quarterly financial results. However, in order to meet the requirements of SEBI Regulation for financial results, the Company has prepared the quarterly financial results for the third quarter of FY 2021-22 and made them IND AS Compliant. Such Ind AS compliant figures relating to the third quarter and period ended 31st December, 21 of the previous year have not been subjected to review/audit by us and have been prepared and presented solely based on the information provided by the management.

**For R.J. Shah & Associates**  
**Chartered Accountants**

**FRN: 109752W**

**R.J. Shah**

**Partner**

**M. No. 034139**

**UDIN: 23034139BGVPQK1122**

**Place: Vadodara**

**Date: February 13, 2023**



**CHEMCRUX ENTERPRISES LIMITED**


CIN : L01110GJ1996PLC029329

Reg. Office : 330, TRIVIA Complex, Natubhai Circle, Race Course, Vadodara - 390007

Statement Of Unaudited Standalone Financial Results For The Quarter & Period Ended December 31, 2022

(All amounts are in INR Lacs, unless otherwise stated)

	Particulars	Quarter Ended			Period Ended	
		31-12-2022 Unaudited	30-09-2022 Unaudited	31-12-2021 Unaudited	31-12-2022 Unaudited	31-12-2021 Unaudited
	<b>Income</b>					
I	Revenue from Operations	2,049.68	2,774.39	2,941.76	7,514.54	6,860.97
II	Other Income	31.44	32.09	50.37	87.63	89.73
III	<b>Total Income (I+II)</b>	<b>2,081.12</b>	<b>2,806.48</b>	<b>2,992.13</b>	<b>7,602.17</b>	<b>6,950.70</b>
	<b>Expenses</b>					
IV	- Cost of Materials Consumed	1,293.12	1,192.95	1,790.74	3,647.42	3,791.07
	- Purchases of Stock-in-Trade	-	-	-	-	-
	- Changes in Inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	-458.00	124.78	-150.46	-98.22	-256.15
	- Employee Benefit expenses	172.92	275.20	135.69	616.23	445.54
	- Finance costs	6.86	13.09	2.91	35.29	10.61
	- Depreciation and Amortisation expenses	54.39	47.85	41.02	146.12	117.78
	- Other expenses	539.37	601.63	526.50	1,715.12	1,451.66
	<b>Total Expenses (IV)</b>	<b>1,608.66</b>	<b>2,255.50</b>	<b>2,346.40</b>	<b>6,061.96</b>	<b>5,560.51</b>
V	<b>Profit before tax (III-IV)</b>	<b>472.46</b>	<b>550.98</b>	<b>645.73</b>	<b>1,540.21</b>	<b>1,390.19</b>
VI	<b>Tax Expense:</b>					
	a) Current tax					
	- Current tax	111.05	128.38	145.75	367.25	345.75
	- Taxes for earlier years	-	-	-	-	-
	b) Deferred Tax (Credit)/Charge	3.57	20.01	6.69	29.50	11.16
	<b>Total tax expense (VI)</b>	<b>114.62</b>	<b>148.39</b>	<b>152.44</b>	<b>396.75</b>	<b>356.91</b>
VII	<b>Profit for the quarter (V-VI)</b>	<b>357.84</b>	<b>402.59</b>	<b>493.29</b>	<b>1,143.46</b>	<b>1,033.28</b>
VIII	<b>Other Comprehensive Income</b>					
	A. (i) Items that will not be reclassified to profit or loss					
	(ii) Income tax relating to items that will not be reclassified to profit or loss					
B	(i) Items that will be reclassified to profit or loss	19.58	8.07	12.10	30.91	13.59
	(ii) Income tax relating to items that will be reclassified to profit or loss	4.93	2.03	3.05	7.78	3.43
	<b>Total Comprehensive Income [B(i)-B(ii)]</b>					
IX	<b>Total Comprehensive Income for the quarter (VII+VIII)</b>	<b>372.49</b>	<b>408.63</b>	<b>502.34</b>	<b>1,166.59</b>	<b>1,043.44</b>
X	<b>Earnings Per Equity Share</b>					
	a) Basic and Diluted ( In Rs.)	2.42	2.72	3.33	7.72	6.98




**Notes to Standalone Financial Results :**

- 1 These Standalone Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 13th February, 2023. The Auditors of the Company have carried out a Limited Review of the above Financials Results for the quarter and period ended 31st December, 2022 in the terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
- 2 The Company migrated from the SME Exchange to the Main Board on 5th May, 2022. Hence, the Company has first-time adopted IND AS during the Year with transition period date of 1st April, 2021. Accordingly, these standalone financial results have been prepared in accordance with the Companies (Indian Accounting Standard) Rule, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 3 Since this is the First Year of implementation of IND AS for the Company, it has opted for the relaxation granted by SEBI Circular dtd. 5th July, 2016 - Para 2.6.1 (ii) and (iii) for the 3rd Quarter of the first year of IND AS implementation, whereby the figures of quarter and period ended 31st December 2021 are presented and are IND AS Compliant but those relating to the year ended 31st March, 2022 are not presented being not mandatory in terms of the said Circular.
- 4 Since the Company was listed on SME Exchange till the end of previous year, it was not preparing quarterly financial results. However, in order to meet the requirements of SEBI Regulation for financial results, the Company has prepared the financial results for the quarter and period ended 31st December of FY 2021-22 and made them IND AS Compliant. Such Ind AS compliant figures relating to the Quarter and Period ended 31st December 2021 have not been subjected to review/audit by the Auditors and have been prepared and presented solely based on the information provided by the management. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
- 5 The Company is primarily engaged in the business of manufacturing and processing of Bulk Drug Intermediates, which in terms of ind AS 108, on Operating Segment, constitute a single operating segment.
- 6 The Reconciliation of the Net Profit worked out for the period ended 31st December 2021 in accordance with Indian GAAP with the Total Comprehensive Income in accordance with Ind AS is given below:

Sr No	Particular	Rs In Lacs
		Period Ended 31st December 2021
1	<b>Net Profit As Per previous GAAP( Indian GAAP)</b>	<b>1,039.46</b>
	Add/(Less):	
2	Amortisation on Right-to-use Asset	-9.26
3	Net Impact of IND AS 116 on Leases	4.31
	Tax on account of above items	-1.24
	<b>Net Profit As Per Ind As</b>	<b>1,033.28</b>
4	Gain on Fair Valuation of Investments	13.59
5	Tax on account of above item	3.43
	<b>Total Comprehensive Income for the period</b>	<b>1,043.44</b>

For & on behalf of the Board  
For Chemcrux Enterprises Limited

  
Girishkumar Shah  
Whole Time Director  
DIN : 00469291



Place : Vadodara  
Date : 13th February, 2023